KHPG(SZ:002773)2021-04-27 16:00Financial Performance - The company's operating revenue for Q1 2021 was ¥914,539,686.01, representing a 44.54% increase compared to ¥632,722,657.18 in the same period last year[2]. - Net profit attributable to shareholders was ¥233,634,223.15, up 32.29% from ¥176,602,308.00 year-on-year[2]. - The net cash flow from operating activities surged by 462.91%, reaching ¥194,488,660.20 compared to ¥34,550,598.16 in the previous year[2]. - The basic earnings per share increased by 25.67% to ¥0.2541 from ¥0.2022 in the same period last year[2]. - Revenue increased by 44.54% compared to the same period last year, primarily due to sales growth[11]. - Operating costs rose by 40.62% year-on-year, attributed to increased sales[11]. - R&D expenses surged by 338.29% year-on-year, reflecting higher investment in research and development[11]. - The company reported a total comprehensive income of CNY 233,418,952.64 for the quarter, compared to CNY 177,162,465.70 in the previous year[33]. - The company reported a net profit for the first quarter of 2021 of CNY 111,067,443.05, a significant increase from CNY 56,688,074.27 in the same period last year, representing a growth of 96.1%[35]. - Operating profit reached CNY 130,658,036.91, compared to CNY 72,273,684.26 in the previous year, indicating an increase of 80.8%[35]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,087,273,270.85, a 1.23% increase from ¥7,001,158,559.94 at the end of the previous year[2]. - The company's current assets totaled CNY 3,955,739,760.51, slightly down from CNY 3,961,851,967.09 at the end of 2020[22]. - The total non-current assets increased to CNY 3,131,533,510.34 from CNY 3,039,306,592.85[23]. - The total liabilities decreased to CNY 1,097,988,873.46 from CNY 1,245,342,681.02[24]. - The company's cash and cash equivalents were CNY 1,383,178,942.04, down from CNY 3,327,670,119.72[22]. - Accounts receivable decreased to CNY 296,568,899.03 from CNY 330,403,148.01[22]. - The inventory value was CNY 236,067,097.02, slightly down from CNY 239,639,530.05[22]. - The total liabilities decreased to CNY 261,113,525.52 from CNY 297,409,471.91, showing improved financial stability[30]. - The total equity increased to CNY 4,712,580,241.65 from CNY 4,601,512,798.60, indicating a strengthening of the company's financial position[30]. Revenue Sources - The pharmaceutical manufacturing segment accounted for 100% of total revenue, with a 44.80% year-on-year increase[3]. - The revenue from biological products saw a significant increase of 86.19%, amounting to ¥30,196.26[4]. - The company received government subsidies totaling ¥21,293,364.85 during the reporting period[5]. - The company received CNY 999,458,661.72 from sales of goods and services, compared to CNY 675,919,905.65 in the previous year, reflecting a growth of 47.8%[37]. Cash Flow - Cash inflow from operating activities totaled CNY 1,015,709,683.92, up from CNY 706,709,972.74, reflecting a growth of 43.6%[38]. - The net cash flow from operating activities was CNY 194,488,660.20, a substantial increase from CNY 34,550,598.16 in the prior year[38]. - The company reported cash outflow from investment activities of CNY 2,197,759,268.17, compared to CNY 1,311,193,335.30 in the previous year, indicating an increase of 67.2%[38]. - The company reported a decrease in cash flow from financing activities, with a net cash flow of -CNY 1,058,902.31 compared to 1,613,854,400.00 in the previous year[39]. - The net cash flow from investment activities was -441,809,479.39 CNY, compared to -184,658,955.90 CNY in the previous period, indicating a significant increase in cash outflow[41]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,701[7]. - The total equity attributable to shareholders rose to CNY 5,989,284,397.39 from CNY 5,755,815,878.92[25]. - The company reported a decrease in employee compensation payable to CNY 23,063,264.70 from CNY 99,401,464.87[24]. Investor Relations - The company has engaged in multiple investor communications, discussing business development and company overview with institutional investors[21]. - The company has maintained a consistent communication strategy with institutional investors throughout the quarter[21].